Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- NEW PRODUCTS
July 23, 2007
- Profits Should Be Transferred from Long-Listed Drugs to New Drugs: Mr Yamabe
July 23, 2007
- New CRT-D Concerto C154DWK, ICD Virtuoso VR: Medtronic
July 23, 2007
- JPMA Proposes “Reported Price Approval System” for New Drugs
July 23, 2007
- EnRhythm Automatically Selects Optimal Pacing Mode: Medtronic
July 23, 2007
- Industry Presents NHI Pricing System Reform Proposals to Health Minister
July 23, 2007
- Cook Conducts Joint Clinical Trial of Zilver PTX Stent in Japan and US
July 23, 2007
- GENERICS NEWS IN BRIEF
July 23, 2007
- Asahi Kasei Medical, Kuraray Medical to Merge Dialysis Business First
July 23, 2007
- Increases in DPC Hospitals Drive Nichi-Iko's Business
July 23, 2007
- MEDICAL DEVICE NEWS IN BRIEF
July 23, 2007
- Nippon Chemiphar to Drastically Shift Priority to Generics
July 23, 2007
- Number of Patients Enrolled in Avastin PMS Exceeds 500 in 1 Month: Chugai
July 23, 2007
- BUSINESS NEWS IN BRIEF
July 23, 2007
- 7 Drugs Transiently Excluded from DPC
July 23, 2007
- Excessive Thoroughness Should Be Eliminated in Source Data Verification: Seminar
July 23, 2007
- Hospital Stay Shortens but Readmission Rate Rises under the Current DPC System
July 23, 2007
- Korosho Calls on Pharmacists to Actively Participate in Anticancer Chemotherapy
July 23, 2007
- MCH to Search Cerebral Infarction Biomarkers with Kyushu Univ.
July 23, 2007
- Evista to Reach \20 Bil. Sales Goal Ahead of Schedule
July 23, 2007
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…